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Abstract
Background: We previously reported cryobiopsy (Cryo) with endobronchial ultrasonography-guide sheath (EBUS-GS)
for peripheral pulmonary lesions (PPLs) provides significantly larger tissues than transbronchial biopsy (TBB) and
provides high quantity and quality DNA for gene analysis by next generation sequencing. However, the tumor cell
yields and programmed death ligand 1 (PD-L1) expression between each approach have not been compared. Here,
we assessed the tumor cell numbers and PD-L1 expression for Cryo with EBUS-GS for PPLs and TBB in patients with
lung cancer.
Methods: Sixteen patients were enrolled in this prospective study from June to November 2017 at Tokyo Women’s
Medical University Hospital. The number of tumor cells from a single biopsy, total number of tumor cells, average
number of tumor cells, and 22C3 PD-L1 expression (≥ 50% and≥ 1%) were compared between Cryo and TBB.
Results: The numbers of tumor cells from a single biopsy, total numbers of tumor cells, and average numbers of
tumor cells obtained by Cryo were significantly larger than those obtained by TBB (Cryo [means ± standard errors of
the means]: 1321 ± 303.7, 1981 ± 411.7, and 1406 ± 310.3; TBB: 208.8 ± 38.24, 1044 ± 189.0, and 208.8 ± 37.81; P < 0.0001,
P = 0.0474, P = 0.0006, respectively). PD-L1≥ 50% and≥ 1% patients for Cryo were 18.8 and 56.3%, respectively, whereas
those for TBB were 12.5 and 37.5%, respectively. The sensitivity, specificity, positive predictive value, negative predictive
value, concordance, and κ coefficient based on Cryo for TBB were 66.7, 100, 100, 92.9, 93.8%, and 0.7647, respectively,
for PD-L1≥ 50%; and 44.4, 71.4, 66.7, 50, 56.3%, and 0.1515, respectively, for PD-L1≥ 1%.
Conclusion: Cryo with EBUS-GS may be a useful diagnostic approach for lung cancer, with advantages over TBB for
gene analysis and whole exon sequencing. Particularly, it could contribute to patients taking pembrolizumab as first-
line therapy when PD-L1 was negative by evaluating TBB specimens. It could also provide ample tissue for PD-L1
expression analysis in addition to accurate diagnosis and gene analysis.
Keywords: Cryobiopsy, The number of tumor cells, Programmed death ligand 1 expression, Endobronchial
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Background
Lung cancer is the most prevalent cause of cancer-re-
lated death worldwide. Peripheral pulmonary lesions
(PPLs) suspicious for lung cancer have been detected at
high frequency following the increased utilization of
computed tomography (CT) of the chest. The 3rd edi-
tion of the American College of Chest Physicians guide-
lines recommends using endobronchial ultrasonography
(EBUS) for PPLs [1]. Transbronchial biopsy (TBB),
transbronchial needle aspiration, and brushing with
EBUS-guide sheath (EBUS-GS) have been recognized as
useful strategies for the diagnosis of PPLs [2–9]. In
addition to diagnostic applications, it is also recom-
mended to validate the programmed death ligand 1 (PD-
L1) expression [10, 11] and maximize the volume of tis-
sue for phenotyping and genotyping [12]. However, tis-
sues from PPLs obtained by conventional biopsy are
generally small [13]. Therefore, cryobiopsy (Cryo) with
EBUS-GS may be a useful tool for overcoming this prob-
lem. Cryo with EBUS-GS has been shown to be a safe
and useful tool for PPLs suspicious of lung cancer [14,
15]. We previously reported that Cryo with EBUS-GS
yields significantly larger tissues than TBB and provides
high quantity and quality DNA for gene analysis by next
generation sequencing. Furthermore, Cryo with EBUS-
GS provides a high concordance between rapid on-site
evaluation and the final diagnosis [14]. However, com-
parisons of tumor cell numbers and PD-L1 expression in
tissues obtained between Cryo and TBB have been un-
known. Because Cryo with EBUS-GS yields larger tissues
than TBB, we hypothesized that Cryo with EBUS-GS
may be able to have more tumor cells and may therefore
be more suitable for evaluation of PD-L1 expression
compared with TBB. Therefore, the purpose of this
study was to assess the tumor cell numbers and PD-L1
expression obtained by Cryo and TBB.
Methods
Ethical considerations
This was a prospective study approved by the Institu-
tional Review Board of Tokyo Women’s Medical Univer-
sity Hospital (date of approval: April 19, 2017; approval
number: 170404). Informed consent was obtained from
all patients before enrollment in this study.
Patient population and study design
The eligibility criteria and exclusion criteria were as pre-
viously described [14]. Eligible patients were over 20
years old and had PPLs suspicious of lung cancer. Pa-
tients were excluded from the study if they showed any
of the following features: bleeding predisposition, plate-
let count < 20,000/mm3, pregnancy, active infection, re-
spiratory insufficiency, lesions less than 2 cm from the
pleura, obvious blood vessels adjacent to EBUS over 0.5
cm, and refusal to participate in the study [14]. In total,
23 patients underwent Cryo with EBUS-GS at Tokyo
Women’s Medical University Hospital, and 16 patients
who were given a diagnosis by biopsy were enrolled in
this study.
PPLs were defined as abnormal and solid shadows in
the pulmonary parenchyma, which were not identified
with bronchoscopy [14, 16], and ground glass nodules
were excluded. All PPLs were identified with CT or 18F-
fluorodeoxy glucose-positron emission tomography prior
to Cryo with EBUS-GS [14]. The lesion size was mea-
sured at the largest diameter [14]. Each patient was
underwent brushing, TBB, and Cryo in this series.
Procedures
The procedures used in this study were described previ-
ously [14]. A flexible fiber bronchoscope (BF-1TQ290;
Olympus, Tokyo, Japan), 20-MHz radial EBUS probe
(UM-S20-20R; Olympus), guide sheath (SG-201C; Olym-
pus), brush (BC-202D-2010; Olympus), forceps (FB-
231D; Olympus), and 1.9 mm cryo probe (CRYO2;
ERBE, Tuebingen, Germany) were employed [14].
Thrombin (Liquid Thrombin MOCHIDA Softbottle 10,
000; Mochida Pharmaceutical, Tokyo, Japan) and bal-
loon catheter (B5-2C; Olympus) were prepared in case
of mild or severe bleeding [14]. Local anesthesia with 1%
lidocaine for nebulizing, 2% lidocaine bolus to the bron-
chus, intravenous injection of 2–2.5 mg of midazolam,
and intra-muscular injection of 35 mg pethidine hydro-
chloride for conscious sedation were used during the
procedures [9, 14]. The blood pressure, oxygen satur-
ation, pulse rate, and electrocardiography of all patients
were monitored in this study [9, 14].
Sampling methods
Sampling methods were previously described [14].
Briefly, all patients were intubated with an endotracheal
tube (7.5 mm TaperGuard; COVIDEN, MN, USA) to
simplify the insertion and removal of the bronchoscope
[14]. After confirmation of PPLs by EBUS and fluoros-
copy, the internal EBUS was removed, leaving behind
GS [3, 4, 14]. EBUS was withdrawn when PPLs were not
identified, and a curette was inserted into GS to move
into the appropriate bronchial segment [3, 14]. The cur-
ette was withdrawn, and EBUS was reinserted into GS to
confirm PPLs under fluoroscopy [3, 14]. Brushing, TBB,
and Cryo were performed in this series to obtain cyto-
logical materials and tissues [14]. Brushes for brushing
were inserted into GS two times consecutively to obtain
cytological materials. The forceps for TBB were inserted
into GS 5 times to obtain tissues [14]. After the Cryo
probe was wetted with alcohol cotton (STERI COTTOα;
Kawamoto, Osaka, Japan) to facilitate smooth insertion
into GS, the Cryo probe was inserted into GS and frozen
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with carbon dioxide for 3–5 s to about − 70 °C 1 or 2
times [14]. Subsequently, the Cryo probe was withdrawn
together with GS and bronchoscope and then thawed in
saline to obtain histological tissue [14]. The brush, for-
ceps, and Cryo probe were washed with saline for cyto-
logical evaluation, cell blocks, bacterial cultures, acid-fast
bacteria cultures, and polymerase chain reaction [14].
Each patient underwent chest radiography to assess po-
tential complications 1 h after bronchoscopy [9, 14].
Sampling process and diagnosis
Sampling process and diagnosis were performed as pre-
viously described [14]. The tissues obtained by Cryo
were cut in half [14]. One of the tissues obtained by
Cryo and the tissue by TBB were immediately fixed with
20% formalin, stained with hematoxylin and eosin (HE)
staining and immunohistochemistry (IHC) staining for
histological evaluation and PD-L1 expression [14]. The
other tissue obtained by Cryo was immediately frozen at
− 80 °C for DNA sequencing analysis [14]. Every patho-
logical specimen was evaluated by an experienced path-
ologist to reach a diagnosis [14].
Evaluation of tumor cell numbers and PD-L1 expression
After the pathologist reached a diagnosis, the number of
tumor cells was counted manually by one cytoscreener
and one pulmonologist in a blinded manner using HE
staining slides. Then, the average number of tumor cells
was calculated.
After sectioning of samples to 4–5 μm, PD-L1 staining
was performed with 22C3 antibodies (rabbit monoclonal,
clone 22C3; Agilent Dako, Glostrup, Denmark) using
autostainer (Autostainer Link 48, Agilent Dako). PD-L1
positivity was defined as membranous staining in at least
1% of cells [10], regardless of staining intensity and pro-
portion in the membrane. PD-L1 was evaluated by expe-
rienced pathologist, and the cut off values were classified
as ≥50% and ≥ 1%. The number of tumor cells by a single
biopsy, total number of tumor cells, average number of
tumor cells, and PD-L1 expression for each patient were
compared between Cryo and TBB.
Data analysis
Data analysis was carried out using Graph Pad PRISM
(GraphPad Software, La Jolla, CA, USA). T-tests were
used to compare the numbers of tumor cells between
Cryo and TBB. Differences with P values of less than
0.05 were considered statistically significant. The odds
ratio (OR), sensitivity, specificity, positive predict value
(PPV), negative predict value (NPV), concordance, and
Cohen’s kappa (κ) coefficient based on Cryo for TBB
were used to assess PD-L1 expression. The concordance
rate was classified according to κ value as slight agree-
ment (0–0.20), fair agreement (0.21–0.40), moderate
agreement (0.41–0.60), substantial agreement (0.61–
0.80), or almost perfect agreement (0.81–1.0) [17].
Results
Baseline characteristics
Patient characteristics, including the number, gender, me-
dian age, smoking history, median size of PPLs, tumor,
nodes, metastasis (TNM) stage, and final diagnosis by
bronchoscope, are summarized in Table 1. We diagnosed
10 adenocarcinomas, 4 squamous cell carcinomas, 1 small
cell lung cancer, and 1 metastatic lung tumor.
Comparison of tumor cell numbers between Cryo and
TBB specimens
Comparisons of tumor cell numbers between Cryo and
TBB are shown in Table 2. The number of tumor cells
obtained from a single biopsy by Cryo was significantly
larger than that by TBB (Cryo [mean ± standard error of
the mean]: 1321 ± 303.7; TBB: 208.8 ± 38.24; 95% confi-
dence interval [CI]: 756.8–1467, P < 0.0001, Fig. 1a). The
total number of tumor cells obtained by Cryo was sig-
nificantly larger than that obtained by TBB (Cryo:
1981 ± 411.7; TBB: 1044 ± 189.0; 95% CI: 11.79–1862,
P = 0.0474, Fig. 1b). Furthermore, the average number of
tumor cells obtained by Cryo was also significantly larger
than that obtained by TBB (Cryo: 1406 ± 310.3; TBB:
208.8 ± 37.81; 95% CI: 558.6–1835, P = 0.0006, Fig. 1c).
Comparison of PD-L1 expression between Cryo and
TBB specimens
Comparisons of PD-L1 expression between Cryo and
TBB are shown in Table 2. Representative image of HE




Median age (range) 69 (46–82)
Smoking history no. (yes/no) 14/2
Median size (cm) of PPLs (range) 3.9 (1–8.1)





Histological subtype no. (%)
Adenocarcinoma 10 (62.5)
Squamous cell carcinoma 4 (25)
Small cell lung cancer 1 (6.25)
Metastatic lung tumor 1 (6.25)
PPLs peripheral pulmonary lesions, TNM tumor, nodes, metastasis
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staining for TBB and Cryo and PD-L1 ≥ 50% for Cryo
with the same patient are shown in Fig. 2. PD-L1 ≥ 50%
was observed in 18.8% of patients for Cryo and 12.5% of
patients for TBB. PD-L1 ≥ 1% was observed in 56.3% of
patients for Cryo and 37.5% of patients for TBB. The
OR, sensitivity, specificity, PPV, NPV, concordance, and
κ coefficient were 45 (95% CI: 1.394–1452), 66.7%
(0.094–0.992), 100% (0.753–1), 100% (0.158–1), 92.9%
(0.661–0.998), 93.8% (0.698–0.998), and 0.7647 (0.288–
1), respectively, for PD-L1 ≥ 50% and 2 (0.244–16.37),
44.4% (0.137–0.788), 71.4% (0.290–0.963), 66.7% (0.223–
0.957), 50% (0.187–0.813), 56.3% (0.299–0.803), and
0.1515 (0–0.608), respectively, for PD-L1 ≥ 1% (Table 3).
Adverse events
There were no clinically serious adverse events, except
mild bleeding in 4 cases; all cases required endoscopic
procedures with thrombin [14].
Discussion
In this study, we described the excellent results of Cryo
with EBUS-GS for PPLs. To the best of our knowledge,
no other studies have reported comparisons of tumor
cell numbers and PD-L1 expression between Cryo and
TBB with EBUS-GS for PPLs. This report provides evi-
dence about comparison of tumor cell numbers and
22C3 PD-L1 expression using Cryo with EBUS-GS.
In our study, the number of tumor cells from a single
biopsy, total number of tumor cells, and average
number of tumor cells obtained by Cryo were signifi-
cantly larger than those obtained by TBB. Cryo with
EBUS-GS had the advantage of yielding significantly
larger specimens than TBB, as we previously reported
[14, 15]. The volume obtained by Cryo was about 26
times greater than that obtained by TBB [14]. There-
fore, the higher volume was expected to contribute to
the significant differences in the number of tumor cells.
Not only did Cryo yield more tumor cells than TBB but
Cryo also showed higher total and average numbers of
tumor cells, suggesting that it may be appropriate to
perform Cryo 1 or 2 times for PPLs suspicious of lung
cancer. In addition, performing Cryo 1 or 2 times
would yield more DNA for subsequent analyses of lung
cancers because the numbers of tumor cells were sig-
nificantly larger than that obtained by TBB, despite per-
forming TBB 5 times. Cryo specimens may be more
appropriate for analyzing gene mutations and perform-
ing whole exon sequencing compared with TBB speci-
mens. Furthermore, despite being cut in half and the
one was used for gene mutation analysis [14], even the
other half of the specimen was sufficient for evaluation
of HE staining and PD-L1 expression. Notably, for PD-
L1 ≥ 50%, we found high specificity (100%), PPV
(100%), NPV (100%), and concordance (93.8%) and sub-
stantial agreement (0.7647) for κ coefficient. In con-
trast, for PD-L1 ≥ 1%, we found low sensitivity (44.4%),
NPV (50%), and concordance (56.3%) and slight agree-
ment (0.1515) for κ coefficient.
Table 2 Comparison of the number of tumor cells from a single biopsy, total number of tumor cells, average number of tumor
cells, and PD-L1 expression between Cryo and TBB
Cryo TBB
Case No. of tumor cells Total no. Average no. PD-L1 (%) No. of tumor cells Total no. Average no. PD-L1 (%)
1 4601 4601 4601 10 634 402 337 332 198 1903 380.6 5
2 381 381 381 0 1622 29 0 0 0 1651 330.2 0
3 25 25 25 0 871 302 140 0 0 1313 262.6 0
4 2080 2080 2080 100 143 98 76 10 8 335 67 100
5 115 115 115 10 3 0 0 0 0 3 0.6 0
6 3509 642 4151 2075.5 10 63 50 25 22 0 160 32 0
7 1467 1467 1467 40 14 0 0 0 0 14 2.8 0
8 532 0 532 266 0 1340 449 30 12 0 1831 366.2 0
9 2248 541 2789 1394.5 0 124 25 0 0 0 149 29.8 0
10 2321 2321 2321 10 334 294 157 124 96 1005 201 0
11 618 0 618 309 5 471 217 169 119 0 976 195.2 0
12 1621 31 1652 826 0 331 222 0 0 0 553 110.6 0
13 5520 121 5641 2820.5 90 1380 137 90 61 7 1675 335 100
14 2301 2301 2301 70 1431 471 145 90 66 2203 440.6 10
15 625 578 1203 601.5 0 311 248 202 198 187 1146 229.2 10
16 1075 740 1815 907.5 0 750 675 302 58 0 1785 357 10
Cryo cryobiopsy, TBB transbronchial biopsy, PD-L1 programmed death ligand 1
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Some studies have assessed the concordance rate of
PD-L1 expression between resected tissues and biopsy
samples [18–20] or tissue microarrays [21]. One study
using a specific hybrid IHC score with 4059 antibody
showed good concordance between resected samples
and TBB for PD-L1 expression [18]. Another study using
positive/negative IHC scores with EPR1161 (2) antibody
showed moderate concordance [19]. Similarly, we dem-
onstrated high specificity, PPV, NPV, and concordance
and substantial agreement for κ coefficient between
Cryo, which showed a significantly larger volume such
as resected specimen than TBB, and TBB for PD-L1 ≥
50%. In contrast, we observed low sensitivity, NPV, and
concordance and slight agreement for κ coefficient for
PD-L1 ≥ 1%. We hypothesized that the reasons for this
discrepancy between previous reports and our results
with regard to PD-L1 ≥ 1% may be related to the use of
different antibody, various scoring systems, and hetero-
geneity of PD-L1 expression.
Some immune checkpoint inhibitors have been proved
to be effective for lung cancer treatment as first-line
monotherapy [11, 22], first-line combination therapy
[23–25], or second-line therapy [10, 26, 27]. However,
pembrolizumab is the only immune checkpoint inhibitor
found to be effective as a first-line monotherapy accord-
ing to the proportion of PD-L1 expression. 22C3 anti-
body, which are regarded as a companion diagnostics,
are associated with pembrolizumab. Accordingly, in this
study, we used 22C3 antibody to detect PD-L1 expres-
sion. Importantly, some studies describing PD-L1 ex-
pression have found it different with various antibodies
[28, 29], and various antibodies have been shown to have
different cut-off values for PD-L1 expression [22–27].
Furthermore, some studies described the intra- and in-
ter-tumor heterogeneity of PD-L1 expression [30–32].
Indeed, heterogeneity is the one of the reasons we had 2
false-positive cases for PD-L1 ≥ 1%. Moreover, Cryo
yielded larger specimens [14] and higher tumor cell
numbers than TBB. These reasons support our above in-
terpretations and may explain the differences in results
for PD-L1 ≥ 1% between previous studies [18, 19] and
our current findings.
Our results regarding PD-L1 expression could contrib-
ute to patients taking pembrolizumab as first-line ther-
apy [22] when PD-L1 was negative by evaluating TBB




Fig. 1 Comparison of the numbers of tumor cells between Cryo and TBB. a, The number of tumor cells obtained by a single biopsy. 1321 ± 303.7
(mean ± SEM) for Cryo, 208.8 ± 38.24 for TBB (95% CI: 756.8–1467, P< 0.0001). b, Total number of tumor cells obtained by each biopsy. 1981 ± 411.7 for
Cryo, 1044 ± 189.0 for TBB (95% CI: 11.79–1862, P= 0.0474). c, Average number of tumor cells obtained by each biopsy. 1406 ± 310.3 for Cryo, 208.8 ± 37.81
for TBB (95% CI: 558.6–1835, P= 0.0006). Cryo, cryobiopsy; TBB transbronchial biopsy; SEM, standard error of the mean; CI, confidence interval
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expression to use Cryo specimens to prevent from lead-
ing to misclassification. Moreover, we showed that Cryo
specimens had the advantages of not only providing tis-
sues for accurate diagnosis and DNA for gene analysis
for personalized therapeutic strategy [14] but providing
ample tissue for evaluating PD-L1 expression.
This study had several limitations. First, it was per-
formed at a single institution with a small number of pa-
tients and did not apply a randomized control design to
validate the results. Second, we compared tumor cell
numbers and PD-L1 expression between Cryo and TBB.
Thus, a comparison of PD-L1 expression between Cryo
and resected tissues should be performed in future stud-
ies. Third, although we used a smaller Cryo probe (1.9
mm), performing Cryo with a larger probe (2.4 mm,
CRYO2; ERBE) may have yielded even larger tissues and
more tumor cells for evaluating gene analysis and PD-L1
expression. However, such an approach may also cause
clinically significant complications. The optimal size of
Cryo probe still remains unknown.
Conclusion
Cryo with EBUS-GS for PPLs is a useful diagnostic strat-
egy. The number, total number, and average number of
tumor cells obtained by Cryo were significantly larger
than those obtained by TBB. Thus, this approach may
be more appropriate for analyzing gene mutations and
whole exon sequencing compared with TBB. These re-
sults could contribute to patients taking pembrolizumab
as first-line therapy when PD-L1 was negative by evalu-
ating TBB specimens. Cryo specimens could have an ad-
vantage of providing ample tissue for evaluating PD-L1
expression in addition to providing tissue for accurate
diagnosis and DNA for gene analysis. Further studies
with larger cohorts are needed to validate these results.
Abbreviations
Cryo with EBUS-GS: Cryobiopsy with endobronchial ultrasonography using a
guide sheath; PD-L1: Programmed death ligand 1; PPLs: Peripheral
pulmonary lesions; TBB: Transbronchial biopsy
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